Moleculin Biotech/$MBRX.O
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Moleculin Biotech
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
- Ticker
- $MBRX.O
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17
- Headquarters
- Houston, United States
- Website
- moleculin.com
MBRX.O Metrics
BasicAdvanced
$7.9M
-
-$191.95
2.00
-
Price and volume
Market cap
$7.9M
Beta
2
52-week high
$10.24
52-week low
$0.16
Average daily volume
198K
Financial strength
Current ratio
0.937
Quick ratio
0.78
Long term debt to equity
0.013
Total debt to equity
0.025
Interest coverage (TTM)
-671.51%
Profitability
EBITDA (TTM)
-28.828
Management effectiveness
Return on assets (TTM)
-84.57%
Return on equity (TTM)
-1,371.64%
Valuation
Price to book
0.25
Price to tangible book (TTM)
6.55
Price to free cash flow (TTM)
-0.002
Free cash flow yield (TTM)
-56,497.18%
Free cash flow per share (TTM)
-149.644
Growth
Earnings per share change (TTM)
-91.34%
MBRX.O Financial Performance
Revenues and expenses
MBRX.O Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.